



AF

1632
TFW

PTO/SB/21 (09-04)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/353,423
	Filing Date	July 15, 1999
	First Named Inventor	Nagabhushan, Tattanahalli L.
	Art Unit	1632
	Examiner Name	Anne Marie Falk
	Attorney Docket Number	016930-001120US
Total Number of Pages in This Submission		

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (2 pgs.) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): -- Form PTO/SB/08A & PTO/SB/08B (2 pgs., submitted in duplicate); -- Copy of European Search Report (7 pgs.); -- 14 References Cited; and -- Return Receipt Postcard.
		Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Chris J. Ullsperger		
Date	December 29, 2005	Reg. No.	48,006

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	KrisAnne Popovits	Date	29 December 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

On: 29 December 2005

TOWNSEND and TOWNSEND and CREW LLP

By: _____

KrisAnne Popovits
KrisAnne Popovits

PATENT
Attorney Docket No.: 016930-001120US
Client Reference No.: CJ0776QK



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Tattanahalli L. Nagabhushan et al.

Application No.: 09/353,423

Filing Date: July 15, 1999

For: **METHODS AND COMPOSITIONS
FOR DELIVERY AND EXPRESSION
OF INTERFERON-ALPHA NUCLEIC
ACIDS**

Customer No.: 20350

Examiner: Anne Marie Falk

Art Unit: 1632

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97 and §1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached forms PTO/SB/08A and PTO/SB/08B (2 pages, submitted in duplicate) are being called to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of all but one (1) of the identified references [in compliance with the requirements of 1287 OG 163] are enclosed; the reference Zhang et al., PNAS, 3(1):4513-4519, April 1996, was previously cited by the U.S. Patent Office in an Office Action dated February 10, 2005. The identified references were cited by the European Patent Office in a related corresponding European application, serial

number EP 05 01 3342. A copy of the European Search Report is also enclosed. This Information Disclosure Statement (IDS) is being filed before the mailing date of the final Office Action or Notice of Allowance.

It is respectfully requested that the cited references be expressly considered during the prosecution of the subject application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

CERTIFICATION

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Chris J. Ullsperger
Reg. No. 48,006

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
CJU:kap



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/353,423
		Filing Date	July 15, 1999
		First Named Inventor	Nagabhushan, Tattanahalli L.
		Art Unit	1632
		Examiner Name	Anne Marie Falk
Sheet 1	of 2	Attorney Docket Number	016930-001120US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	US-			
	AB	US-			
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			
	AS	US-			
	AT	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AU	DE	42 38 778		05-19-1994	MAX DELBRUECK CENTRUM (DE)		<input checked="" type="checkbox"/>
	AV	DE	44 07 859		03-02-1995	MAX PLANCK GESELLSCHAFT (DE)		<input checked="" type="checkbox"/>
	AW	WO	95/05835		03-02-1995	BAYLOR COLLEGE OF MEDICINE		<input type="checkbox"/>
	AX	WO	95/11984		05-04-1995	CANJI, INC.		<input type="checkbox"/>
	AY	WO	95/19434		07-20-1995	CALYDON, INC.		<input type="checkbox"/>
	AZ	EP	0 704 534		04-03-1996	SUMITOMO PHARMACEUTICALS COMPANY, LIMITED		<input type="checkbox"/>
	BA	WO	97/25072		07-17-1997	CANJI, INC.		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60667923 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/353,423	
			Filing Date	July 15, 1999	
			First Named Inventor	Nagabhushan, Tattanahalli L.	
			Art Unit	1632	
			Examiner Name	Anne Marie Falk	
Sheet	2	of	2	Attorney Docket Number	016930-001120US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BB	GOEDDEL, D.V. et al. "The structure of eight distinct cloned human leukocyte interferon cDNAs." <i>Nature</i> (March 1981), 290:20-26.	
	BC	HOCHKEPPEL, H.K. et al. "Human IFN-alpha hybrids." <i>Drugs of the Future</i> (1992), 17(10):899-914.	
	BD	FERRANTINI, M. et al. "α ₁ -Interferon Gene Transfer into Metastatic Friend Leukemia Cells Abrogated Tumorigenicity in Immunocompetent Mice: Antitumor Therapy by Means of Interferon-producing Cells." <i>Cancer Research</i> (March 1993), 53:1107-1112.	
	BE	WILLS, K.N. et al. "Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer." <i>Human Gene Therapy</i> (September 1994), 5(9):1079-1088.	
	BF	ZHANG, J.F. et al. "Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression." <i>Cancer Gene Therapy</i> (January 1996), 3(1):31-38.	
	BG	ABRAHAM, N.G. et al. "Gene Transfer of Alpha-Interferon (IFN- α) into Hematopoietic Stem Cells in Chronic Myelogenous Leukemia (CML)." <i>Experimental Hematology</i> (August 1996), 24(9):1053.	
	BH	AHMED, T. et al. "Gene Transfer of Alpha Interferon into Hematopoietic Stem Cells." <i>Leukemia Research</i> (1998), 22(2):119-124.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.